Prospective use of miRNAs as biomarkers in the diagnosis of Alzheimer’s disease
Open Access
- 19 December 2024
- journal article
- research article
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 34 (6) , 1025-1037
Abstract
Alzheimer's disease (AD) is the leading cause of dementia in the aging population. Pathogenic processes related to the accumulation of amyloid plaques (Aβ) and intracellular neurofibrillary tangles (NFTs) begin during the asymptomatic stage long before the onset of deterioration in cognitive functions and neurodegeneration, which makes rapid diagnosis and treatment difficult. Although biochemical diagnostic markers isolated from the body fluids of AD patients are currently used, scientists are engaged in research into molecular biomarkers that will significantly accelerate the diagnosis long before the first clinical symptoms appear. The research presented here focused on microRNAs (miRNAs), small, non-coding RNA molecules that are involved in the regulation of the post-transcriptional expression of many genes. A review of the literature revealed that miRNAs play an important role in regulating the expression of genes involved in the pathophysiological mechanisms of AD. Changes in the levels of miRNAs in a patient's body fluids can be used for rapid diagnosis. Original scientific articles published between 2014 and 2023 describing clinical and experimental studies on the role and expression levels of various miRNAs were selected from scientific databases such as PubMed, NCBI, Science Direct, and Google Scholar. The selected miRNAs were divided into 2 groups based on their expression level in AD: those with increased expression and those with decreased expression. A review of the latest scientific reports confirms that miRNAs may be a promising source of non-invasive and widely available biomarkers. Additionally, their modulation may prove to be an effective therapeutic strategy in AD.Keywords
This publication has 70 references indexed in Scilit:
- Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive changeActa Neuropathologica, 2022
- Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community studyAlzheimer's & Dementia, 2021
- MicroRNA Expression Signature in Mild Cognitive Impairment Due to Alzheimer’s DiseaseMolecular Neurobiology, 2020
- Cognitive Decline and Modulation of Alzheimer’s Disease-Related Genes After Inhibition of MicroRNA-101 in Mouse Hippocampal NeuronsMolecular Neurobiology, 2020
- Mechanism of microRNA‐22 in regulating neuroinflammation in Alzheimer’s diseaseBrain and Behavior, 2020
- The paradox of opposite directions of gene expressions in MCI and AD suggests possible therapy to prevent progression of MCI to ADAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2020
- An investigation of microRNA‐103 and microRNA‐107 as potential blood‐based biomarkers for disease risk and progression of Alzheimer's diseaseJournal of Clinical Laboratory Analysis, 2019
- Systematic Review of miRNA as Biomarkers in Alzheimer’s DiseaseMolecular Neurobiology, 2019
- miR-200a-3p promotes β-Amyloid-induced neuronal apoptosis through down-regulation of SIRT1 in Alzheimer’s diseaseJournal of Biosciences, 2017
- Regulation of Neurotropic Signaling by the Inducible, NF-kB-Sensitive miRNA-125b in Alzheimer's Disease (AD) and in Primary Human Neuronal-Glial (HNG) CellsMolecular Neurobiology, 2013